Board Changes

Phytopharm PLC 09 January 2007 Company Contact: U.K. Investor Relations Contact: Phytopharm plc Financial Dynamics Dr Daryl Rees David Yates Mr Piers Morgan Ben Atwell +44 1480 437 697 +44 207 831 3113 www.phytopharm.com Board Changes GODMANCHESTER, Cambridgeshire, U.K. (9th January 2007) - Phytopharm plc (LSE: PYM; NASDAQBB: PHYOF; PHYOY) ('Phytopharm' or the 'Company') today announces a number of planned changes to its senior management team ahead of the next phase in its development. Dr Richard Dixey, Phytopharm's co-founder who has led the Company over the last ten years, is stepping down as Chief Executive Officer and Board Director. He is succeeded as Chief Executive Officer by Dr Daryl Rees who has served as Phytopharm's Chief Operating Officer for the past six years. Dr Rees will focus on generating growth and value from Phytopharm's strong product portfolio, in particular its Hoodia gordonii functional food obesity programme which is partnered with Unilever and its Myogane and Cogane pharmaceutical neurological products, which are currently in Phase I and II clinical development respectively. Phytopharm is also pleased to announce today the appointment of Mr Piers Morgan as Chief Financial Officer and Board Director. Mr Morgan has an MA in Law and Management Studies from Cambridge University and is a Chartered Accountant. He worked at Close Brothers Corporate Finance on a wide variety of Equity Capital Market and Mergers & Acquisitions transactions and was a founding director of the Life Sciences Mergers & Acquisitions team at Ernst & Young. In 2000, he joined Arrow Therapeutics Limited as Finance Director, raising significant finance through private equity, debt and grants. In 2005, he moved to Paris to become Chief Financial Officer of BioAlliance SA, where he led the successful flotation of the company on Euronext Paris. There are no further disclosures to be made under paragraphs 9.6.13R of the Listing Rules and 3.1.2R of the Disclosures Rules in respect of Mr Morgan. All Board changes are with immediate effect and form part of the planned restructuring of the Board. Dr Richard Dixey has confirmed that he has no current intention to sell any shares in Phytopharm and he and Chakra Limited (a Company which Dr Dixey holds 50 per cent of the share capital) have agreed not to dispose of their interests in the ordinary shares of the Company for a period of 6 months from today's date. For a further period of 3 months, any disposals of their interests in the ordinary shares of the Company will be through the Company's appointed stockbroker only. Commenting, Dr Paul Whitney, Chairman, said: 'On behalf of the Board of Phytopharm and myself personally, I would like to thank Richard Dixey for his enthusiasm, energy and pivotal contribution to the development of Phytopharm over the past ten years. We wish him well in his future activities.' Dr Richard Dixey added: 'I have thoroughly enjoyed my time leading Phytopharm and I am delighted to be handing over the CEO's role to Daryl Rees. He has been instrumental in the success of Phytopharm's product development to date and with the strong addition of Piers Morgan to the Board as CFO, I believe the Company is well placed for much-deserved success.' -ENDS- NOTES TO EDITORS Phytopharm plc Phytopharm is a pharmaceutical development and functional food company whose product leads are generated from medicinal plant extracts. The Company's strategy is to develop these products through 'proof of principle' clinical testing, and then secure partners for late stage development, sales and marketing. This business model generates a lean cash burn and all laboratory, manufacturing and clinical work is outsourced to specialists while core competencies such as strategy and management are kept in-house. This operational structure allows access to advanced research techniques whilst maintaining low fixed overheads and a lower development cost structure. More information concerning Phytopharm's activities can be found on its website at http://www.phytopharm.com This information is provided by RNS The company news service from the London Stock Exchange